Sign Up Today and Learn More About AiCure Stock
Invest in or calculate the value of your shares in AiCure or other pre-IPO companies through EquityZen's platform.
AiCure Stock (AICU)
AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress.
About AiCure Stock
Founded
2010
Headquarters
New York, NY, US
Total Funding
27.3M
Industries
Software, Data and Analytics, Science and Engineering
AiCure Press Mentions
Stay in the know about the latest news on AiCure
AI-Enabled Drug Discovery and Clinical Trials Research Report 2025-2035 Featuring AiCure, Aitia, Atomwise, BenevolentAI, Insilico Medicine, PathAI, Recursion, Saama, Schroedinger, Tempus, Unlearn.ai
globenewswire • Jun 10, 2025
AiCure Appoints Sabina Chadha as CEO, Ed Ikeguchi Transitions to Chief Medical Officer, and Josh Wilson Promoted to COO and President
prnewswire • May 29, 2025
Artificial Intelligence (AI) in Clinical Trials Market Insights, Competitive Landscape, and Forecasts Report 2025-2032 Featuring Key Players Such as TEMPUS, NetraMark, ConcertAI, AiCure, and Oracle
globenewswire • May 17, 2025
US Computer Vision in Healthcare Market worth US$11.53 billion by 2029 with 24.0% CAGR | MarketsandMarkets™
prnewswire • Apr 11, 2025
AiCure Bringing New Patient Engagement Platform H.Code to DPHARM 2024
businesswire • Sep 10, 2024
AiCure Management
Leadership team at AiCure
Chief Product Officer
Michelle Marlborough
Co-Founder & CSO
Laura Shafner
Join now and verify your accreditation status to gain access to:
- AiCure Current Valuation
- AiCure Stock Price
- AiCure Management
- Available deals in AiCure and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- AiCure Cap Table and Funding History by Share Class and Liquidity Preferences
- AiCure Revenue and Financials
- AiCure Highlights
- AiCure Business Model
- AiCure Risk Factors
- AiCure Research Report from SACRA Research
Trading AiCure Stock
How to invest in AiCure stock?
Accredited investors can buy pre-IPO stock in companies like AiCure through EquityZen funds. These investments are made available by existing AiCure shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell AiCure stock?
Shareholders can sell their AiCure stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
